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Abstract 
S EN SORY REG RESSION T IME FROM SUBARACHNOID BLOCK WITH 
HYPERBARIC 0.75% BUP IVACA INE IN THE OBESE PAT IENT 
George L. Hilton, BBA, BSN 
School of Allied Health Professions, Virginia Commonwealth 
University, 19 89 
Major Director : Charles H. Moore, MS, CRNA 
The purpose of this study was to determine if obese 
patients have a different sensory regression time from 
subarachnoid block than non-obese patients using hyperbaric 
0.75% bupivacaine. A quasi-experimental design was used. 
Twenty patients were separated into two groups; one group 
was classified as obese, and the other group was classified 
as non-obese. The data consisting of age, height, weight, 
sex, and surgical procedure were recorded preoperatively. 
All the patients received hyperbaric 0.75% bupivacaine via 
subarachnoid puncture. The levels of spinal anesthesia 
were recorded at the highest level achieved. The injection 
time was also recorded. When the surgery was completed, 
the patient was transferred to the recovery room and levels 
of sensory blockade were checked by pin-prick with an 
18-gauge needle every 10 minutes until complete recovery 
viii 
from the spinal anesthesia had been achieved. 
The hypothesis, there will be no difference in sensory 
regression time from SAB with hyperbaric 0.75% bupivacaine 
between obese and non-obese patients, failed to be 
rejected. No statistically significant difference, using 
linear regression analysis, was found in mean regression 
time between groups (obese versus non-obese) . 
Chapter One 
Introduction 
Subarachnoid block (SAB) was first reported by Dr. 
Corning in 1885. He made his discovery while experimenting 
with cocaine as a local anesthetic in a dog. Subsequently, 
Augusta Beard in 189 8 refined the SAB technique. This 
technique was studied ln many different ways; however, 
there was little current research published addressing 
obesity and the effect it had on sensory regression time. 
A prolonged block can cause many problems for the 
patient, such as anxiety, financial expense in terms of a 
longer period of time spent in the recovery room, and risk 
of an accident due to loss of sensation and motor control. 
An insufficient block requires the patient to have an 
additional anesthetic for the same surgical procedure, and 
exposes the patient to additional risks and complications. 
By acquiring the knowledge of sensory regression time from 
SAB in obese patients, it is possible to plan accordingly 
for obese patients in terms of preoperative teaching, 
preparation, type and dose of local anesthetic to use, and 
postoperative care. Increased knowledge from research in 
1 
this area will benefit patients in terms of safety, 
comfort, cost, and convenience. 
Statement of Purpose 
The purpose of this study was to determine if obese 
patients have a different sensory regression time from 
subarachnoid block than non-obese patients using 
hyperbaric, 0.75% bupivacaine. 
statement of Problem 
Is the sensory regression time from SAB with 
hyperbaric, 0.75% bupivacaine different in the obese and 
non-obese patient? 
Hypothesis 
2 
There is no difference in sensory regression time from 
SAB with hyperbaric, 0.75% bupivacaine, between obese and 
non-obese patients. 
Variables 
Dependent. The dependent variable was the time for 
sensory regression from SAB. 
I ndependent. The independent variable was body 
weight. 
Significance 
3 
I nc reased kn owled ge gained f rom this study will help 
clinician s p rovide a safe r an d mo re cost effective SAB fo r 
obese patients. Knowledge gained f rom this study will also 
help the clinician p repa re the patient fo r the SAB 
p rocedu re and decrease patient anxiety. Othe r gains 
include dec reased cost to the patient in te rms of time 
spent in the recove ry room and dec reased risk of injury to 
the patient due to loss of sensation and moto r cont rol. 
Definition of Te rms 
Obese. Patients whose body weight is above thei r 
weight range acco rding to the chart of Desi rable weights 
fo r Men and Women p repa red by the Met ropolitan Li fe 
Insurance Company ( 19 80) ( see Appendix B) a re classified as 
obese . 
Non-obese. Patients whose body weight is within thei r 
weight range according to the cha rt of Desi rable Weights 
for Men and Women p repa red by the Met ropolitan Li fe 
Insurance Company ( 19 80) ( see Appendix B )  a re classi fied as 
obese. 
Sensory reg ression time . Following a SAB , the time 
r�ui red fo r a patient to have complete retu rn of a "sha rp" 
sensation from the stimulus of an 18-gauge needle . This 
sensation is intact f rom the nipple line to the tip of the 
2nd an d 3rd toes bilaterally. 
Suba rachnoid block. Anesthesia p rod uced by injecting 
hype rba ric, 0.75% bupivacaine by mean s of a 25-gauge spinal 
n eedle into the subarachnoid space through a lumbar 
vertebral space, either at L2- 3, L3-4, or L4-s. 
0.75% Bupivacaine. An amide type local anesthetic 
commonly used to produce analgesia when injected into the 
subarachn oid space. The concentration used in this study 
contained 7.5 milligrams of bupivacaine per milliliter of 
solution ( mg/ml). 
4 
Hyperbaric. A solution heavier than that solution 
into which it is injected. Dextrose is a common additive 
used to make solutions hyperbaric. The concentration used 
in this study contained 84 mg/ml. 
Assumptions 
1. There were no defects in the spinal anatomy of the 
patients. 
2. The spinal anesthetic "hyperbaric 0.75% bupivacaine 
in 8.4% dextrose " was pure and the dose per ampule was 
accurate as indicated on the label. 
3. The dose of local anesthetic given was presumed to 
be adequate to produce T4 level sensory analgesia in all 
patients. 
4. Each subject possessed a normal blood acid-base 
balance. 
5. Scales were uniformly accurate between patients. 
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Limitations 
1. The methodology included a lack of randomization, 
with unequivalent comparison groups. 
2. The individual may have performed an inconsistent 
assessment of sensory levels due to patient differences in 
the perception of sharpness. 
3. More than one individual performed the assessments 
of the levels of anesthesia, and there may have been 
different judgments about where the level of anesthesia was 
actually located. 
4. The individual could be biased in his or her 
judgment regarding the anesthesia level because of 
preconceived ideas about what effect obesity had on the 
recovery time from SAB. 
Delimitations 
1. Patients could only be studied if they agreed to 
participate. 
2. Informed consent was required. 
3. All patients were accurately weighed on the same 
scale prior to surgery . 
4. All patients were female presenting for postpartum 
bilateral tubal ligations. 
Conceptual Framework 
Introduction. Patients who are obese or pregnant 
experience higher levels of analgesia following SAB when 
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compared to non -obese or non-pregnant patients given a 
similar dose of bupivacaine anesthetic ( McCulloch & 
Littlewood, 19 86). Since there are several reasons to 
explain these higher sensory levels, it is necessary to 
discuss the basic anatomy of the spinal column, production 
and flow of cerebrospinal fluid, blood supply to the spinal 
cord, local anesthetic site and mechanism of action, local 
anesthetic spread and duration of action, and the local 
anesthetic bupivacaine. 
Anatomy of the vertebral column. The vertebral column 
consists of seven cervical, twelve thoracic, five lumbar, 
five sacral and usually, four coccygeal vertebrae. There 
are four curves in the vertebral column cervical, thoracic, 
lumbar, and pelvic ( Bridenbaugh & Kennedy, 19 80). Normally, 
the cervical and lumbar curves are convex anteriorly and 
the thoracic and pelvic curves are concave anteriorly. 
These curves affect the spread of local anesthetic in the 
subarachnoid space ( Smith, 19 68). The upper lumbar and 
lower thoracic vertebral canal is inclined anteriorly in 
the supine patient 8 to 12 degrees. These inclined 
vertebrae cause a more cephalad spread of hyperbaric 
analgesics to the fourth or fifth thoracic segments. 
There are three main ligaments that provide the spinal 
column stability and flexibility. The ligaments preceding 
from a ventral to dorsal direction are as follows. The 
ligamentum flavum covers the interlaminar space. The 
interspinous ligament connects the spinous processes and 
blends dorsally with the supraspinous ligaments. The 
supraspinous ligament connects the apices of the spinous 
processes from cervical vertebrae number seven to the 
sacrum (Bridenbaugh & Kennedy, 1980). 
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Exposure of spinal nerves to local anesthetic causes 
sensory blockade and analgesia to the corresponding 
dermatomes. There are 3 1  pairs of spinal ne rves arranged 
as follows : eight cervical, twelve thoracic, five lumbar, 
five sacral, and one coccygeal. The spinal nerves leave 
the vertebral canal by passing through the intervertebral 
foramina. The union of ventral and dorsal roots form the 
spinal nerves. The ventral roots contain axons of motor 
neurons, and the dorsal roots contain axons of sensory 
neurons (Bridenbaugh & Kennedy, 1980). 
Cerebrospinal fluid. Cerebrospinal fluid (CSF) is 
formed in the choroid plexus and is an ultrafiltrate of 
blood (Bridenbaugh & Kennedy, 1980). It is a clear, 
colorless fluid found in the spinal and cranial 
subarachnoid spaces and in the ventricles of the brain. It 
has a pH of 7.4 to 7.6 and a specific gravity of 1.003 to 
1.009. The electrolyte concentrations similar to that of 
plasma but with a sodium and chloride ion content slightly 
higher and a protein content slightly lower. The total 
volume of CSF in the average adult ranges from 120 ml to 
150 ml with 25 ml to 3 5  ml in the spinal subarachnoid 
space. The pressure of the CSF ranges from 60 millimeters 
of water (mm H20) to 80 mm H20. According to Bridenbaugh 
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and Kennedy (1980), cerebrospinal fluid flows from the 
fourth ventricle to the two foramen of Lushka, and under 
the influence of the cephalad circulation in the vertebral 
vein s circulates upward over the surface of the brain. It 
also passes through the median foramen of Magen die and then 
proceeds downward to the spinal cord. The composition of 
the CSF is kept constant by osmosis alterations in posture, 
and arterial pulsations. Cerebrospinal fluid passes back 
into the bloodstream by filtration and osmosis, which takes 
place in the supratentorial region of the brain through the 
arachn oid villi and granulations. 
Blood supply. There are one anterior and two 
posterior spinal arteries that supply blood to the spinal 
cord ( Bridenbaugh & Kennedy, 1980). The anterior spinal 
artery descends in front of the anterior longitudinal 
sulcus of the spinal cord to the filum terminale. Many 
vessels branch off the anterior spinal artery to encircle 
the spinal cord and supply its periphery. The posterior 
spinal arteries send penetrating branches into the 
posterior white and gray matter. These branches freely 
connect with the anterior spinal artery. 
Blood is drained from the spinal cord by two ascen ding 
vertebral veins that lie posterior and lateral to the 
spinal cord. These veins become engorged in the obese 
individual, especially when the patient is in the supine 
position. I t  is the blood flowing in the cephalad 
direction in the vertebral venous system that influences 
the cephalad movement of CSF. 
Local anesthetic site and mechanism of action. 
9 
According to Howarth (194 9), when a local anesthetic was 
injected into the subarachnoid space, it was absorbed by 
neural elements. It was believed the spinal nerve roots 
are the site of action of local anesthetics; however, the 
exact site of action was debatable. Howarth discovered 
that radioactive-isotope- labeled local anesthetics gathered 
around the lateral and posterior aspects of the spinal 
cord, as well as along the spinal nerve roots. Howarth 
postulated that local anesthetics act by reducing the 
permeability of the cell membrane to sodium ions so that 
there was a marked depression of the rate of depolarization 
such that it failed to reach threshold potential. 
Consequently, an action potential did not occur and neural 
blockade resulted. 
There were three theories regarding the exact 
mechanism that resulted in neural blockade from the 
administration of local anesthetics ( Strichartz ,  1 97 3). 
First, the receptor site theory stated that local 
anesthetics bind to receptors in sodium channels. 
Strichartz reported that the sodium channel gates must be 
open for local anesthetic to enter and to block ionic 
conduction through the nerve. Strichartz postulated that 
the quartenary molecules of the local anesthetics bind to 
open sodium channels resulting in blocked neural 
conduction. Lee (1979) suggested four possible sites for 
action of the local anesthetics on sodium channels ( a) 
within the pore, ( b) on protein surfaces exposed to the 
aqueous phase, ( c) at the lipid-protein-water interface, 
and ( d) within the membrane. 
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Second, the membrane expansion theory stated that 
local anesthetics expand nerve membranes that in turn block 
the sodium channels and neural conduction. The nerve 
membrane was regarded as being essentially impermeable to 
cations except at special regions where holes or channels 
exist through which cations move during an action 
potential. Anesthetic agents were postulated to increase 
the freedom of movement of the lipid molecules, especially 
at the aqueous-lipid interface, with the result that some 
part of the membrane that is critical for conduction is in 
an expanded state ( Ritchie, 1975). 
Third, the surface charge stated that the local 
anesthetic agent was bound to the membrane by the 
lipophilic, aromatic end of the molecule with its cationic 
head remaining in solution. As a result, the fixed 
negative charges on the membrane were neutrali zed so that 
the resting potential across the membrane increased 
considerably. I f  this increase in transmembrane potential 
was great enough, the action potential might be 
insufficient to reduce the membrane potential to its 
threshold level and a conduction block occurred ( Ritchie, 
1975). 
1 1  
According to Wood (1982), there were three properties 
that had an influence on the action of local anesthetics. 
They included lipid solubility, protein binding, and the 
dissociation constant ( pKa). It was the lipophylic portion 
of the drug molecule that penetrated the cell membrane. 
The more lipophylic the local an esthetic ; the more potent 
and longer acting was the drug. Increased lipid solubility 
of the local anesthetic caused more extensive entry into 
body membranes and tissues. Anesthetic action was 
prolonged by increased protein binding. As the local 
anesthetic releases from the protein; the n eural blockade 
continues. 
The pKa is the pH at which the drug is 50% ioniz ed and 
50% un-ioniz ed. Local anesthetics, including bupivacaine, 
are weak bases. Weak bases are more ioniz ed in an acidic 
solution, so decreasing the pH increases the ioni zation of 
the base. The closer the pKa is to physiologic pH, the 
more un -ionized form of the drug is available to cross the 
cell membran e and to have a faster onset of action ( Wood, 
1 982). 
Local anesthetic spread. Local anesthetic spread 
refers to the movement of the local anesthetic after it is 
injected into the subarachn oid space. The spread of a 
local anesthetic solution, after it was injected into the 
CSF, has an effect on sensory regression time. The 
addition of a glucose solution (7.5-1 0% )  to a local 
anesthetic produces a hyperbaric solution that influences 
12 
the spread of local anesthetic. Gravity influences the 
movement of a hyperbaric solution, when injected into the 
subarachnoid space. If the patient remains in a sitting 
position, the hyperbaric solution moves in the caudad 
direction. Placing the patient in a Trendelenberg position 
facilitates a cephalad spread of the anesthetic drug. A 
hyperbaric solution becomes isobaric within 10 to 15 
minutes after injection into the CSF. At this point, the 
level of anesthesia becomes "fixed" and changes in patient 
position do not affect the anesthetic level (Norris, 1988). 
There are patient characteristics that affect the 
spread of local anesthetics in CSF. As the age of the 
patient increases, the onset of the local anesthetic is 
faster and it takes longer for the anesthetic to be 
metaboliz ed and cleared from the body (Veering, Burm, & 
Spierdijk, 1988). 
Patient height also influences local anesthetic 
spread. According to Greene (1985), a "short" person who 
has a local anesthetic injected at the L3 -4 interspace will 
have a more cephalad spread of anesthesia than a "tall" 
person with the same amount and type of local anesthetic. 
Even if the anesthetic solution spreads an equal distance 
in both patients, an 18 centimeter (cm) spread reaches a 
higher spinal segmental level in a "short" patient. 
There are also height-related di fferences in CSF 
volume. The volume of CSF below the L2 interspace is 
greater in "tall" patients because the length of the cauda 
13 
equina is greater (Norris, 1988). Since the CSF volume at 
the L2-L5 interspace, where the local anesthetic is 
injected, is greater in "tall" patients, the anesthetic 
solution has greater dilution and hence less cephalad 
spread. The depth of the subarachnoid space (from the dura 
to the pia matter) is greater in "tall" patients. The 
increased depth means there is an increase in absolute CSF 
volume at any level of the cord that contributes to further 
dilution of the local anesthetic in the CSF (Norris, 1988). 
The site of injection of local anesthetic into the 
subarachnoid is important to note. Above L2, the spinal 
cord occupies a larger portion of the subarachnoid space 
that subsequently decreases the amount of CSF. Therefore, 
less dilution of the local anesthetic occurs with greater 
cephalad distribution (Norris, 1988). 
According to Greene (1985), the direction of the bevel 
of the spinal needle during injection had no effect on the 
spread of local anesthetics in the subarachnoid space. 
Greene cited studies that indicated turbulence, as a result 
of the rate or force of injection, did not have any 
clinically significant effect on local anesthetic spread in 
the CSF. Furthermore, Greene reported that sudden 
increases in CSF pressure from uterine contractions, 
valsalva maneuver, straining or coughing did not increase 
the spread of local anesthetics in the subarachnoid space. 
According to Norris (1988), the dose of anesthetic 
affects its spread in the CSF. It is generally found that 
14 
a higher dose of local anesthetic results in a more 
cephalad spread of the drug in the CSF. However, the 
influence of concentration, volume, and baricity may 
override the effect of a higher dosage of local anesthetic. 
Assessment of local anesthetic spread. Rocco , 
Raymond, Murray, Dhingra, and Freiberger (1985) 
demonstrated loss of sensation to touch as the best method 
of assessing sensation after SAB. Sensation to pin-prick 
and cold were also studied. Most practitioners in 
anesthesia today use pin-prick to assess sensory levels. 
Local anesthetic duration of action. The duration of 
analgesia is influenced by the speed of absorption from the 
subarachnoid space into the bloodstream. The egress of 
local anesthetic agents following subarachnoid injection is 
primarily by vascular absorption with no hydrolysis or 
other form of degradation taking place in the spinal fluid 
(Bridenbaugh & Kennedy, 1980) . Local anesthetic 
concentration decreased rapidly in the CSF after injection 
because the drug is bound to tissue and absorbed into the 
bloodstream. Spinal anesthesia duration is controlled by 
the speed that the local anesthetic is absorbed from the 
spinal cord, the subarachnoid space, and di f fusion throug h 
the dura and the epidural space. The more absorptive 
surface the local anesthetic is exposed to as it spreads in 
the subarachnoid space, the shorter the duration of 
anesthesia. 
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According to Ritchie and Greene (1985), the 
lipophylicity of the local anesthetic also affects its 
duration. Tetracaine is highly lipid soluble and lasts 2 
to 3 hours as a spinal anesthetic. Lidocaine is less lipid 
sol uble and only lasts approximately 1 hour. Bupivacaine 
is highly lipid soluble and has a duration of 2.5 to 4 
hours. 
Bupivacaine. Bupivacaine is an amid� type local 
anesthetic. It has a molecular weight of 288 and a pKa of 
8. 1. Bupivacaine has a lipid solubility partition 
coefficient of 28 and is 95% bound to plasma proteins. 
Onset of action of bupivacaine is very rapid with maximum 
motor blockade and maximum dermatome level achieved within 
15 minutes. Bupivacaine' s duration of action, when 
injected into the subarachnoid space, is reported by the 
manufacturer to be approximately 4 hours. This is 
considered to be an intermediate length of time as compared 
to other local anesthetics. The half life of bupivacaine 
is approximately 2.7 hours. On a potency scale of one to 
eight, bupivacaine has a rating of eight (Savarese & 
Covino, 1 986). 
Metabolism of bupivacaine. Amide type local 
anesthetics are metabolized in the liver via conjugation 
with glucouronic acid. The major metabolite 
"pipecolylxylidine" is excreted by the kidney. Only 6% of 
bupivacaine is excreted unchanged in the urine (Boyes, 
1975). 
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Obesity. When given a similar dose of local 
anesthetic, obese patients experience higher sensory levels 
following SAB when compared to normal weight patients. 
There are several reasons that explain the higher sensory 
levels. The primary reason relates to the decreased amount 
of CSF in obese patients. Other reasons .include slower 
speed of absorption and decreased susceptibility at the 
nerve roots to local anesthetics (McCulloch & Littlewood, 
1986). 
According to McCulloch and Littlewood (1986), obese 
patients, in the supine position, have a decreased CSF 
capacity in their subarachnoid space. Less CSF is 
available to mix with the anesthetic agent; therefore, 
less dilution of the local anesthetic occurs. A reduced 
dose of local anesthetic is required to anestheti ze the 
spinal segments. Blood volume and CSF volume have an 
inverse relationship with one another. I nferior vena cava 
compression produced by a large amount of abdominal fat 
causes lumbar vertebral venous engorgement that decreases 
the subarachnoid space capacity for CSF (Barclay, Renegar & 
Nelson, 1968). Occluding inferior vena cava blood flow 
causes a subsequent increase in blood flow through the 
lumbar vertebral plexus, the ascending lumbar veins, and 
the vertebral venous system (Robinson, 19 49 ). 
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One of the causes of pressure change in CSF is a 
pressure change in the vertebral venous system. The 
vertebral venous system has partially collapsed elastic 
vessels that allow substantial volume increases without a 
pressure increase. There is an inverse relationship 
between vertebral venous system blood volume and CSF volume 
in the subarachnoid space. This explains the decreased 
requirement for local anesthetic in the subarachnoid space 
of both obese and pregnant patients (Barclay et al., 1968). 
Decreased CSF volume might cause a greater spread of 
local anesthetic when placed in the subarachnoid space. 
This phenomenon was demonstrated by the use of an abdominal 
binder to cause abdominal compression and thereby, a 
decrease in the siz e  of the subarachnoid space. Barclay et 
ale (1968), demonstrated that increased pressure from the 
binder caused increased spread of local anesthetic placed 
In the subarachnoid space. 
There are obese patients that hypoventilate due to the 
large amounts of abdominal fat that restrict breathing 
efforts. These patients demonstrate hypercapnia and 
hypoxia. The hypoxic patients are slightly acidotic and 
have a lower physiologic pH. At the same time, an increase 
in cardiac output and alveolar ventilation is needed to 
provide for the increased metabolic needs of obese 
patients, resulting in an increase in both oxygen 
consumption and carbon dioxide (C02) production. It is 
difficult for the respiratory system to meet this increased 
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metabolic demand because of the excess fat. The increased 
chest wall and abdominal adipose tissue produce a decrease 
in chest wall compliance that in turn reduces lung volume. 
There is a decrease in functional residual capacity (PRe) 
and the increase in closing volume of the lungs causes 
perfusion to non-ventilated portions of the lungs. All of 
these changes result in arterial hypoxemia in obese 
patients (Vaughn, 1982). 
Since the pKa of bupivacaine is 8.1, it is considered 
a weak base. Weak bases are more ionized in an acidic 
solution, as may be the case of the blood in obese 
patients. 
the base. 
Decreasing the pH increases the ionization of 
In obese patient, there may be more of the 
ioni zed than the un-ionized form of bupivacaine in the 
bloodstream. These patients will have less drug available 
to cross the cell membrane and hence, bupivacaine will have 
a slower onset of action. 
Bupivacaine clearance is dependent on hepatic blood 
f low. Obese patients have a decreased hepatic blood flow 
due to changes, such as cirrhosis and fatty infiltration 
(Widman, 1975). Bupivacaine clearance may be prolonged in 
the obese patient. 
Drug distributional changes alter bupivacaine 
elimination despite a lack of change in metabolic clearance 
(Abernethy, Greenblatt, Divoll, Harmatz ,  & Shader, 1 981). 
The extent of drug distribution into excess body fat is 
related to the solubility characteristics of the drug. 
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Abern ethy et al., discovered that antipyrine, a low lipid 
soluble drug, was distributed into excess body fat in small 
amounts. However, diaz epam, a highly lipophylic compound, 
distributes disproportionately into excess body fat. 
Diazepam would have a slower clearing capacity due to its 
distribution into excess body fat. The relationship of 
this concept to bupivacaine in an obese patient is worth 
consideration. Bupivacaine is a highly lipid soluble drug 
(it has a lipid solubility partition coefficient of 28). 
Excess extradural fat, as in the obese patient, is readily 
available for bupivacaine distribution after SAB. This 
results in prolonged absorption into the bloodstream and 
prolonged clearance from the body. 
Summary. It can be concluded from the above 
discussion that bupivacaine leaves the CSF and enters the 
blood stream via a concentration gradient. If the 
elimination half-life of bupivacaine is prolonged in the 
obese patient due to in creased distribution into fat, there 
will be less of a concentration gradient of bupivacaine 
between CSF and blood. Bupivacaine will remain in the CSF 
for a longer period of time. I f  this theory is true, the 
spinal nerve roots in obese patients will be exposed to 
bupivacaine for a prolonged time period resulting in a 
prolonged sensory block. Also, obese patients have a 
decreased CSF volume; therefore, the spinal nerve roots are 
exposed to an anesthetic solution with less dilution which 
will have a greater cephalad spread. This will lead to a 
prolonged sensory regression time from a bupivacaine SAB. 
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Chapter Two 
Review of Literature 
Bupivacaine Clearance in Obese Patients 
Abernethy and Greenblatt (1984) studied lipophilic 
drugs, such as bupivacaine. The population consisted of 56 
men and women. Thirty-one of the patients were normal body 
weight, and 25 were obese. They were all healthy adults 
who were not taking medications. None of the patients had 
congestive heart failure or renal failure, and they all had 
normal liver function. 
These lipophilic drugs were shown to have marked 
increases in volume of distribution (Vd) and minimal change 
in clearance resulting in a prolonged elimination half-life 
and a prolonged time to reach steady-state plasma drug 
concentrations. The prolongation of the elimination 
h alf-life in obesity was due to the marked increase in the 
Vd with no significant difference in rate of drug 
clearance. 
Obese patients have decreased hepatic blood flow due 
to changes, such as cirr hosis or fatty infiltration of the 
liver. Since hepatic blood flow is decreased in obese 
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patients, local anesthetic clearance will also be decreased 
(Abernethy & Greenblatt, 1984). It is expected that the 
obese group will have a prolonged sensory regression time 
when compared to the non-obese group. 
Effect of Body Mass on the Spread of Spinal Anesthesia 
Pitkanen (1987) performed a study to determine if 
there was a relationship between weight, -height, and the 
spread of spinal anesthesia. The population consisted of 
90 orthopedic patients, ASA I or I I, having surgery on 
their lower extremities. The first 50 patients were 
anesthetiz ed by SAB using 3 ml of 0. 75% isobaric 
bupivacaine. The remaining 4 0  patients were randomly 
selected to receive 3 ml of hyperbaric or isobaric 0. 75% 
bupivacaine. The patients were divided into two groups. 
One group consisted of patients with a normal body mass 
index (BM I), defined as 20.2 to 24 .6 for females and 21.1 
to 25.9 for males. The other group consisted of patients 
with a BM I greater than 3 0. All patients were placed in 
the lateral position for the SAB, and a lumbar puncture was 
performed at the L3-4 interspace. Three milliliters of 
0.5% bupivacaine were injected and the patients were placed 
in the supine posicion. Responses to pin-prick sensation 
and motor blockade were recorded every 1 0  minutes for the 
first hour after injection. 
Body mass index and sensory level of analgesia are of 
interest to this study. The subarachnoid space is 
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significantly different in the obese versus the non-obese 
patient. An individual with a high body mass index should 
have a higher sensory block when equivalent doses and 
volumes of anesthetics are injected into the subarachnoid 
space as compared to non-obese patients. Pitkanen's (1987) 
conclusions are consistent and support this theory. 
There is a lack of clarity in the methodology making 
this study impossible to repeat based solely on the 
information presented ln the article. It is particularly 
unclear why the author selected 50 patients to receive a 
hyperbaric s olution and 4 0  patients to receive a hype rbaric 
or isobaric solution. It is also unclear as to the method 
used to select the 4 0  patients receiving the hyperbaric or 
isobaric solution of bupivacaine and how the patients were 
divided into obese and non-obese groups. 
The Effect of pH on Anesthetiz ed Nerves 
Ritchie (1975) demonstrated that the pH of the 
solution surrounding the anestheti zed nerve was crucial to 
the effect of the neural blockade. Non-myelinated fibers 
of a nerve were bathed in a long-acting local anesthetic 
until blockade had occurred. The anesthetic solution was 
then removed. No recovery of conduction occurred as long 
as the nerve was maintained in a neutral bathing solution. 
However, when the pH of the bathing solution was increased, 
conduction was restored. When the nerve was returned to a 
neutral bathing solution, conduction block again occurred. 
24 
Conduction could be restored and abolished repeatedly by 
switching the nerve between the alkaline and neutral 
bathing solutions. The conclusion was that the uncharged 
form was relatively inactive whereas; the charged form 
produced local anesthesia. 
The obese patient might have a lower pH CSF when 
compared to the non-obese patient. This would result in 
more local anesthetic in the charged and .active form when 
compared to the non-obese patient. It would be predictable 
that for this reason the obese patient would have a longer 
sensory regression time than the non-obese patient. 
Ritchie's (1975) study was very clear in the 
methodology and would be easy to repeat. It supported the 
theory that the pH of the environment into which the local 
anesthetic was injected was crucial to the sensory 
blockade. It also supported the theory that it was the 
charged form of the local anesthetic that was active in 
blocking nerve conduction. 
Effects of Volume of Spinal Anesthetic in the Subarachnoid 
Space 
Sundnes, Vaagnes, Skretting, Lind, and Edstrom (1982) 
showed that the duration of analgesia increased with larger 
volumes of hyperbaric bupivacaine. All of the patients 
were undergoing urological surgery and were randomly 
assigned to receive 0.5% bupivacaine 1.5 ml, 2.0 mI, or 3.0 
ml in 8.0% glucose. The results of this study showed that 
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the maximum spread and duration of analgesia increased with 
volume. 
The authors did not report the relationship of dose to 
volume of 0.5% bupivacaine. It was conceivable that the 
dose of bupivacaine could have been equal in each case with 
the diluent added to increase the volume or CSF aspirated 
from the subarachnoid space immediately prior to injection 
to increase the volume required for their. study. I f  this 
is indeed the case, their results were consistent with 
Norris' (1988) findings that maximum spread and duration of 
analgesia increases with increased volume of anesthetic in 
the subarachnoid space. 
Inferior Vena Cava Compression 
Barclay et ale (1968) , demonstrated that venous 
compression affects the amount of CSF in the subarachnoid 
space. The purpose of this study was to demonstrate that 
compression of the inferior vena cava by an abdominal 
binder or by a pregnant uterus resulted in vertebral venous 
system engorgement that then decreased the si z e  of the 
subarachnoid space and thus, the amount of CSF. Therefore, 
less anesthetic agent would be necessary to induce spinal 
anesthesia. The sample consisted of three groups. Group 
one consisted of 20 nonpregnant control patients of 
childbearing age who received a spinal anesthetic prior to 
hysterectomy or other gynecological surgery. Group two 
consisted of 15 pregnant patients at term who received a 
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spinal anesthetic prior to cesarean section or delivery in 
the late stages of labor. Group three was an experimental 
group of 15 patients of childbearing age whose inferior 
vena cava pressure was artificially increased to 
approximately 250 mm of water, and who then received a 
spinal anesthetic for a gynecological operation. 
The patients in group three had a femoral catheter 
inserted into the inferior vena cava and-connected to a 
transducer to monitor pressures in the vessel. Prior to 
the injection of an anesthetic agent, the abdomen was 
compressed with an inflatable rubber bladder until the 
inferior vena cava pressure was 250 mm of water. Each 
patient was placed in the lateral Sims position and a 
lumbar puncture was performed at the L3-4 interspace with a 
19-9auge spinal needle. The projecting shaft of the needle 
was bent parallel to the patient's back as the patient 
shifted into the supine position. Four milligrams of 
tetracaine (1.0 ml of a hyperbaric solution) was injected 
as a test dose. The level of analgesia was assessed by 
checking for the loss of sensation to pin-prick and was 
recorded according to a standard dermatome chart. 
The results were as follows: Group one, all of the 
levels of anesthesia fell below the umbilicus except for 
two patients; Group two, all the levels were above the 
umbilicus, with two being higher than T7; Group three, all 
the levels were higher than the umbilicus, with two being 
at T5. The mean level in group one was TIl; in group two 
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it was T8; and in group three it was T7. The authors 
concluded there was a reciprocal relationship between 
venous blood volume and CSF volume that caused a decrease 
in CSF volume in the subarachnoid space after compression 
of the inferior vena cava by a pregnant uterus or an 
abdominal binder. 
A decreased amount of CSF volume indicated there is 
less dilution of the local anesthetic af�er it is injected 
into the subarachnoid space. This results in a larger 
amount of local anesthetic being available to bathe the 
spinal nerve roots. The decreased CSF volume also results 
in a more cephalad spread of the local anesthetic. This 
may explain why pregnant patients during the last half of 
gestation and obese patients require less anesthetic agent 
for spinal analgesia. 
Influence of Obesity on Spinal Analgesia 
McCulloch and Littlewood (1986) performed a study on 
the influence of obesity on spinal analgesia with isobaric 
0.5% bupivacaine. In this study, the height of the block 
in relation to obesity was the main focus. They gave 50 
patients, aged 51 to 89 years, 4 ml of 0.5% bupivacaine and 
correlated the height of blockade and the degree of 
obesity. The authors concluded that increased obesity 
resulted in higher levels of sensory blockade. McCulloch 
and Littlewood speculated on the reasons for this higher 
sensory blockade, such as, increased vertebral blood flow, 
fat deposits, and compression from abdominal fat, all 
impinging on the subarachnoid space. 
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Additional useful information could have been added to 
this study by correlating obesity with sensory regression 
time. This added information would have strengthened these 
authors' conclusions. In addition, there have been no 
studies published to date that correlate obesity with 
sensory regression time from subarachnoid.block with 
isobaric or hyperbaric bupivacaine. 
Chapter Three 
Methodololgy 
Research Design 
A quasi-experimental design was used �o determine if 
obesity affects the regression time from a SASe The 
patients were separated into two groups; one group was 
classified as obese and the other group as non-obese. The 
demographic data consisted of age, height, weight, and sex. 
All patients had the same surgical procedure, a postpartum 
bilateral tubal ligation. The sensory levels were recorded 
in the operating room using a standard dermatome chart (see 
Appendix C) until the highest level was achieved. This 
sensory level was then recorded on the data collection 
form. The sensory levels were also recorded on the data 
collection record immediately upon arrival in the recovery 
room and continued until sensation was restored at the tip 
of the 2nd and 3rd toes bilaterally. 
Population, Sample, and Setting 
The population consisted of inpatients at a 
mid-Atlantic, university, teaching hospital. The sample 
consisted of female patients presenting for postpartum 
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tubal ligations. They were all ASA I-I I  classifications, 
without major obstetrical or medical problems. A 
convenience sample was selected from the operating room 
schedule. All the procedures were performed In an 
operating room of an obstetrical unit. 
Data Collection 
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The patients were interviewed immediately prior to the 
procedure. All the patients were weighed, had an 
intravenous line started, and were preloaded with 2 liters 
of lactated Ringer's solution. While in the sitting 
position a 25-gauge spinal needle was used to perform a 
subarachnoid puncture either at L2-3, L3-4, or L4 -5 spinal 
interspace. An appropriate dose, based on the pa tient's 
height and weight, of 10 to 15 mg of 0.75% bupivacaine in 
8.4 % dextrose was then injected. Patients were immediately 
placed in the Trendelenberg position. The dose of 
bupivacaine, the time of injection, and the highest level 
of sensory blockade were recorded. When the surgery was 
completed the patients were transferred to the recovery 
room. Levels of sensory blockade were checked every 10 
minutes until recovery from the SAB was achieved at the tip 
of the patient's 2nd and 3rd toes bilaterally. Total 
sensory regression time was calculated from the time of 
injection until the previously described sensory recovery 
was achieved. 
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The patient's age, weight, height, sex, and surgical 
procedure were recorded on the data collection form. The 
time and level of sensory blockade was checked using 
pin-prick from an IS-gauge needle bilaterally until sensory 
recovery was achieved. The Dermatome Chart from Cousin's 
(19S0) textbook, Neural Blockade, was used to record the 
actual level at which loss and recovery of sensation was 
noted (see Appendix C). 
Instrumentation 
Reliability and validity of tool. Each spinal nerve 
provides innervation to a segmental field or portion of the 
skin called a dermatome. By pin-pricking the dermatome 
areas on the patient who has received a SAB, one can assess 
whether or not the patient has sensation in that particular 
area of the skin. Lack of sensation indicates the spinal 
nerve innervating that area was "blocked" by the injection 
of the local anesthetic into the subarachnoid space. 
The Dermatome Chart's (see Appendix C) validity has 
been determined throughout the years by its daily use in 
the clinical setting. A Dermatome Chart can be found in 
any basic anatomy book. Dermatome Charts are printed as 
posters, papers, and on clipboards for use clinically. 
Therefore, it is reasonable to conclude that the Dermatome 
Chart is a valid, reliable, and commonly used tool for 
assessment of sensory levels. 
Consent 
Approval for this study was obtained from the 
Committee for the Conduct of Human Research (CCH R). Each 
patient received a verbal explanation about the study and 
was requested to sign a form of written consent (see 
Appendix A). 
Analysis 
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A regression analysis was used to build an analytical 
model. This model explained the relationship between the 
dependent and independent variables. A Q value less than 
.05 was required for significance. 
Chapter Four 
Results 
The sample consisted of 20 female patients divided 
into two groups (see Table 1). Ten patients were obese, 
weighing 137 to 203 pounds, age 22 to 37 years old, and 
height from 59 to 67 inches. Ten patients were non-obese, 
weighing 125 to 179 pounds, age 19 to 31 years old, and 
height from 61 to 68 inches. All 20 patients received the 
same operative procedure, a postpartum bilateral tubal 
ligation (BTL). The variables recorded were: (a) time 
from subarachnoid injection to sensory recovery (the 
dependent variable), (b) age, (c) weight, (d) height, and 
(e) dose (the independent variables). 
The mean dose of hyperbaric 0.75% bupivacaine for the 
combined group was 12.25 mg with the mean dose for obese 
group 12.30 mg, and the mean dose for the non-obese group, 
12.20 mg. The mean weight for the combined groups was 154 
pounds with the mean for the obese group 178 pounds, and 
the mean for the non-obese group 130 pounds. Patient 
weight in each group was measured. The maximum and minimum 
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Table 1 
Means, Standard Deviations, Minimum Values, and Maximum 
Values, for Age, Weight, Height, Dose, and Regression Time 
Variable 
Time 
Weight 
Dose 
Height 
Age 
Variable 
Time 
Weight 
Dose 
Height 
Age 
variable 
Time 
Weight 
Dose 
Height 
Age 
N 
20 
20 
20 
20 
20 
n 
10 
10 
10 
10 
10 
n 
10 
10 
10 
10 
10 
All 
Mean 
155.20 
154.35 
12.25 
63.85 
26.20 
Mean 
157.4 0 
178.20 
12.20 
64 .00 
27.50 
Groups Combined 
SD 
16.4 4 
28.00 
1.20 
2.2 3  
3.83 
Obese Group 
SD 
18.77 
18.04 
1.39 
2.35 
3.68 
Non-obese Group 
Mean 
152.80 
130.50 
12.30 
63.70 
24 .90 
SD 
14 .36 
8.08 
1.05 
2.21 
3.78 
Min 
125 
- 118 
10 
59 
19 
Min 
137 
14 2 
10 
59 
22 
Min 
125 
118 
11 
61 
19 
Max 
195 
203 
15 
68 
33 
Max 
195 
203 
15 
67 
3 3  
Max 
179 
14 5 
15 
68 
31 
Note. Number of patients (n), Minimum Value (Min), Maxi mum 
Value ( Max), Age (years), Weight (pounds), Height (inches), 
Time (minutes), Dose (milligrams). 
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weights in the obese group were 203 and 14 2 pounds, and in 
the non-obese group 179 and 125 pounds. The time for 
sensory regression was also measured. The maximum and 
minimum time in the obese group was 195 minutes and 1 37 
minutes, and in the non-obese group 179 minutes and 1 25 
minutes. The mean sensory regression time for the obese 
group was 157.4 minutes, and for the non-obese group was 
152.8 minutes. There we re no significant - va riables at a £ 
.05 level. 
All va riables in this study we re t reated as 
continuous. Regression an alysis was used to build a model 
t ll a t  explained the relationship between time and the other 
vari ables. A stepwise model building procedure was used to 
determine which of the independent variables were important 
in predicting senso ry regression time. Each vari able in 
the regression model had a level of significance 
calculated. Dose had the most significant £-value of the 
vari ables included in the model (£ = .15). Weight, 
however, was the va ri able of inte rest for this study. The 
following model was tested : 
Y = BO + (Bl) (Xl) + (B2) (X2) 
Legend: Y = Time, Xl = Weight, X2 = Dose, BO = Ave rage of 
Time, Bl = change in Y fo r a unit change in Xl, B2 = change 
in Y for a unit change in X2 
The coefficients of each selected independent va ri able 
were calculated. The value for BO was 79. 091 ;  the value 
for Bl was .094 ; the value for B2 was 5.026. An R-square 
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value was calculated to determine the amount of variability 
in time that can be explained by the above mode. An 
R-square value of .16 78 was found. The hypothesis that 80 
= 81 = 82 = 0 was tested. The E value of .2099 was found. 
The following figures show sensory regression time 
from SAB and weight (see Figure 1), age (see Figure 2) , 
height (see Figure 3) , and dose of bupivacaine (see Figure 
4) • 
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(milligrams of bupivacaine in 8.4 % dextrose) 
Chapter Five 
Discussion 
It is not possible to single out all of the factors 
that may effect sensory regression time in obese patients. 
It is likely that a combination of factors are involved, 
such as, decreased amount of C SF in the subarachnoid space, 
decreased pH due to some degree of hypoventilation that may 
result in slower speed of absorption of local anesthetic, 
and increased volume of blood f lowing through the vertebral 
veins and around the subarachnoid space. In addition, the 
magnitude of these changes may be weight dependent. 
Using a convenience sample from the operating room 
schedule, the patients may not have been obese enough to 
have a significant di fference in sensory regression time 
when compared to the non-obese patients. Indeed, the 
di fference in the mean weight between the obese and 
non-obese groups is 48 pounds. 
Patients receiving larger doses of bupivacaine, such 
as 15 mg, had signif icantly longer sensory regression 
times. This finding was consistent with Greene ' s  ( 1 9 85) 
study. Statistical analysis revealed no difference in mean 
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reg ression time when height and age we re studied. This was 
not consistent with the results of G reene ' s  (1 985) and 
No r ris ' (1 988) studies. G reene reported that inc reasing 
age resulted in increased time fo r sensory reg ression from 
SAB. This inconsistency between Greene ' s  results and the 
results in this study could be explained. G reene ' s  study 
compa red patients that we re aged 60 or o1ger to a younge r 
population that resulted in a la rge age diffe rence between 
the g roups. In this study, all the patients we re 
relatively young, less than 34 yea rs of age, with a mean 
diffe rence between the obese and non-obese g roups of only 
2.4 years. It could also be postulated that the failu re to 
show a significant diffe rence in regression time when 
analyzing the height of the patients was due to the small 
diffe rence, 8 i n ches, between the tallest and shortest 
patient. 
Difficulties with Study 
It was necessa ry, due to occasional conflicting 
clinical and class obligations, for othe r in dividuals to 
assist in data collection. Du ring those occasions, the 
recove ry room nu rses, after inst ruction, assisted by 
pe rfo rming the senso ry level physical assessments. 
The mean diffe rence in weight between the obese and 
non-obese g roups was 4 8  pounds. The re we re seve ral 
patients close to the limits of the weight range. In these 
cases just a few pounds more or less would have put an 
obese patient in the non-obese group and vice versa. 
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Postpartum bilateral tubal ligations were elective 
procedures. On several occasions, a patient scheduled for 
a BTL would be delayed due to other more urgent procedures, 
such as a cesarean section. During the delay, the patient 
frequently changed her mind about proceeding with the BTL. 
Conclusion 
There were no variab les at the Q < . 05 level. An 
R-square value of .17 was found, meaning there is a only 
small positi ve relationship between sensory regression time 
and patient weight and dose. The hypothesis, there will be 
no difference in sensory regression time from SAB with 
hyperbaric 0.75% bupivacaine, between obese and non-obese 
patients, failed to be rejected. 
Sug gestions for Future Research 
The small weight difference between the obese group and 
the non-obese group and the small sample si ze may be 
responsible for the lack of di fference in sensory 
regression time from SAB. Repeating this study with an 
increased sample siz e  and patients selected according to a 
defined weight range, such as morbidly obese, may res ult in 
a more signi ficant di fference in sensory regression times. 
It will be easy to include, in a repeat study, a test of 
the pH of the CS F of all the patients to determine if a 
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correlation exists between pH and sensory regression time. 
Another factor that may have an influence on sensory 
regression time is gender. This study can be repeated with 
male patients having a different surgical procedure, such 
as inguinal hernia repair, to see if there is a difference 
in sensory regression time between obese and non-obese male 
patients. Several other factors that may influence 
regression time, such as age, type of surgical procedure, 
height o f  t he patient, and height of sensory block achieved 
can also be studied. Although it is unlikely one f a c tor 
can be considered the cause of regression time differences, 
the results of these stud i es will have clinical 
application. 
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1. Introduction 
Appendix A 
CONS ENT FO RM 
George Hilton, RRNA I I  
Department of Nurse Anesthesia 
MCV office phone 6-9 808 
Home phone 
I am investigating the duration of the spinal 
anesthetic bupivacaine. You have been selected as a 
candidate to participate in this study because spinal 
anesthesia is appropriate for your surgical procedure. 
2. Benefits 
50 
Bupivacaine is a long acting spinal anesthetic . It 
has a duration of 2.5 to 4 hours with lingering pain 
suppression for many more hours. Your participatio n in 
this study will h elp document the duration of a bupivacaine 
spinal anesthetic. That information may then be used to 
predict more precisely the duration of this anesthetic. 
3. Alternative Therapy 
You have been selected as a candidate for this study 
because spinal anesthetic has been determin ed to be the 
most appropriate form of anesthetic for your ca se. I f  you 
do not want spinal anesthetic, there are other forms of 
anesthesia, such as general anes thesia and epidural 
anesthesia that I can discuss wit h  you. 
4. Risks, I nconveniences, Discomforts 
The risks associated with this study are the same 
risks associat ed with spinal anesthesia. One of t hose 
risks is the risk of neurologic problems from damage t o  a 
nerve. The risk of this complica tion is one in 1 0, 000. 
There is also a risk that you may have a headache that is 
caused by the spinal anesthesia procedure. There are 
remedies available that are 9 9% effective for this risk . 
51 
Assessment of the level of anesthesia is a current 
practice in the recovery area. For this study we will 
assess the level of anesthesia every 1 0  t o  20 minutes un til 
you have completely recovered. It is necessary to 
regularly assess the level of spinal anesthesia during your 
recovery. There will be no addit ional inconvenience to you 
as a result of participa ting in this s tudy. 
5 .  Cost of Participation 
There is n o  cost t o  you above the normal fee for 
spinal anes thesia . 
6. Pregnancy 
Spinal anes thesia has a recogni zed use during labor 
and delivery. In ad dition, bupivacaine SAB has no known 
adverse effect s  on your baby . 
7 .  Research Relat ed I nj ury 
There are no risks of injury associated with this 
study other than those associated with spinal anesthesia 
discussed above. 
8. Confidentiality of Records 
52 
The information that I obtain from you during this 
study will remain confidential. I have taken steps to 
assure that your name and hospitali zation number are not 
associated with the data collection record. Therefore, no 
future reference can be made to you as a result of this 
study. 
9. Withdrawal 
If you have any questions regarding the study you are 
encouraged to ask them now or at any time during the study. 
In addition, you may withdraw from the study at anytime. 
"You understand that in the event of any physical and/or 
mental injury resulting from my participation in this 
research project, Virginia Commonwealth University will not 
offer compensation." 
signed, ____________________ __ Witness ____________________ _ 
date ______________________ _ date ______________________ __ 
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Appendix B 
Chart of Desirable Weight for Men and Women 
D ESIRABLE WEIGHTS FOR MEN 
Accord ing to He igh t  and F rame .  Ages 25 - 59 
WEIGHT IN POUNDS ( I N  I NDOOR CLOTHING) 
HEIGHT ( IN SHOES) 
5' 2" . . . . . . . . . . . . . . . . . . . . . . . . . .  
3" . . . . . _ . . . .  . . . . . . . . . . . . . . . . .  
4" 
5" 
. . . . . . . . . . . . . . . . . . . . . . . . . . . 
• • • • • • • • • • • • •  " 0  • • • • • • • • • • •  
6" . . . . . . . . . . . . . . . . . . .  , . . . . . . .  
7" . . . . . . . . . . . . . . . . . . . . . . . . . . . 
8" . . . . . . . . . . . . . . . . . . . . . . . . . . .  
9" 
1 0" 
1 1  " 
6' 0" 
I "  
2" 
3" 
4" 
• • • • • • • • • • • •  0 • • • • • • • • • • • • • •  
• • • • • • • • • • •  _ .  , _  • • • • •  0 • • • •  • 
• • • • • • • • • • • • • •  0 • •  0 • •  0 _  • • • •  
0 • • • • • • • • • • • • •  0 • • • • • • • • • • •  
• • • • • • • • • • • • • • •  0 • • • • •  0 • • • • •  
. . . . . . . . . . . . . . . . . . . . . .  - . . . . 
• • • • • • • • • • • • • • • • • • •  _ • • • •  0 • •  
• • • • • • • • • • •  0 • •  • • • • • • • • • • • •  • 
SMALL FRAME 
1 28- 1 34 
130- 1 36  
1 32 - 1 38  
1 34 - 1 40 
1 36- 1 42 
1 38- 1 45 
1 40- 1 48 
1 42- 1 5 1  
1 44 - 1 54  
1 46- 1 57 
1 49- 1 60  
1 52 - 1 64  
1 55- 1 68  
1 58- 1 72 
1 62- 1 76 
MEDIUM FRAME LARGE F R A M E  
1 3 1 - 1 4 1  1 38- 1 50  
1 33- 1 43 140- 1 53 
1 35- 1 45 142- 1 56  
1 37- 148 1 44 - 1 60  
1 39- 1 5 1  1 46- 1 64 
1 42- 1 54  1 49- 1 68  
1 45- 1 57 1 52- 1 72 
1 48- 16C 1 55 - 1 76 
1 5 1 - 1 63 1 58- 1 80 
1 54- 166 1 6 1 - 1 84 
1 57- 1 70 1 64 - 1 88  
1 60- 1 74 1 68 - 1 92 
1 64 - 1 78 1 72 - 1 97 
1 67- 1 82 1 76-202 
1 7 1 - 1 87 1 8 1 -207 
------- - -
DES IRABLE  WEIGHTS FOR WOMEN 
Accord ing to He igh t  and Frame.  Ages  25-59 
WEIGHT IN POUNDS ( I N  IN DOOR CLOTHING)  
HE IGHT ( IN  SHOES)  
SMALL FRAME MED IUM FRAME LA RGE FRAME 
4' 1 0" . . . . . . . . . . . . . . . . . . .  . . . . . . .  1 02 - 1 1 1  1 09 - 1 2 1  1 1 8 - 1 3 1  
I I " • • • • • • • • • • • • • • • • • • • • • • • •  0 • 
5'0" 
I "  
2" 
J' 
4" 
5" 
6" 
7" 
8" 
9" 
1 0  
1 1  
6'0:: 
· . 
· . 
. . . . . . . . . . . . . . . . . . . . . . . . .  
• • • • • • • •  _ • • • • • • • • • • • •  0 "  
. '  • •  0 • •  0 0 0 .  e o  • • •  o .  0 0 0 . 0  • • • •  
• • • • •  0 . 0  • •  0 • •  0 • •  0 0 .  0 0 • • •  ' .  
• • •  0 .  0 • • • •  0 .  • • • • 0 0 • • • • • • • 0 • 
· . • • •  0 • • •  0 . 0  • •  0 0 0  0 • • • •  0 • • •  0 
0 • •  0 • •  0 .  0 . '  0 • •  0 "  0 0 • • • • • •  
· . • • • • • • • •  0 • •  0 • •  0 0 • • • • •  ' • • •  
· . . ,  • • • • • • • •  0 • •  0 ·  • • • •  • • • •  • •  
. . . .  , • • • • • • •  0 • • • • •  0 • •  0 • • • • •  
• •  0 ·  • • • •  ' 0  . ,  • • • •  0 • • •  e o  • •  0 
. . .  • ' • •  0 0 .  , . . . . . . . .  , . 
0 . 0 · · · · · · · · · · · · · · · · ·  • 
• •  • • •  0 
. . . .  . 
1 03- 1 1 3 1 1 1 - 1 23 1 20- 1 34 
104 - 1 1 5  1 1 3 - 1 26 1 22- 1 37 
1 06- 1 1 8  1 1 5- 1 29 1 25- 1 40 
1 08 - 1 2 1  1 1 8 - 1 32 1 28- 1 43 
1 1 1 - 124 1 2 1 - 1 35 1 3 1 - 1 47 
1 1 4 - 1 27 1 24 - 1 38 1 34 - 1 5 1  
1 1 7 - 1 30 1 27- 1 4 1  1 37- 1 55 
1 20- 1 33 1 30 - 1 44 1 40- 1 59 
1 23- 1 36  1 33- 147  1 43 - 1 63 
1 26- 1 39 1 36- 1 50 1 46- 1 67 
1 29- 1 42 1 39- 1 53 1 49- 1 70 
1 32- 145 W- I 56  1 52 - 1 73 
1 35- 1 48 1 45- 1 59 1 55- 1 76 
1 38- 1 5 1  1 48 - 1 62 1 58 - 1 79 
No te  Prepared by the Met ropol i tan L i f e  Insur  ance Company Derived p r i m a r i l y  f rom data of the  t979 Bui ld Study Society o f  
,lfIes and ASSOC i a t i o n  o f  L i f e  tnsur ance Medical D i rectors of America t 980  
54 
N o t e . From D e s i rab l e  We igh t s  f o r  Me n/De s i rab l e  We ights for 
Wome n , by Met ropo l i t a n  Li f e  I n surance Company , 1 9 8 0 , 
s o c i e ty o f  Actua r i e s  and A s s oc i a t i on o f  L i f e  I n s u r a n c e  
Med i c a l  D i re c t o r s  o f  Ame r i c a . 
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Appendix C 
Dermatome Chart 
Note. From Neural Blockade ( p. 262) by M. J. Cousins and 
P. o .  Bridenbaugh ( Eds.), 1980 , Philadelphia: J. B. 
Lippincott Company. 
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Appendix D 
Data Sheet 
Age: Weight: Height: Sex: 
Procedure: 
Bupivacaine dosage: 
I njection time of bupivacaine in Operating Room: 
Highest sensory level achieved in operating room: 
In recovery room sensory levels every 10 minutes: 
Time: Level: · Time: Level: , 
Time: Level: · Time: Level: , 
Time: Level: · Time: Level: , 
Time: Level: · Time: Level: , 
Time: Level: · Time: Level: , 
Time: Level: · Time: Level: , 
Time: Level: · Time: Level: , 
Time: Level: · Time: Level: , 
Time: Level: · Time: Level: , 
Time: Level: · Time: Level: , 
Total time of sensory block: 
Comments: 
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Vita 
